Obsidian Therapeutics Reports $50.7 Million Q3 Net Loss, $324.4 Million in Cash

Obsidian Therapeutics reported a third-quarter 2026 net loss of $50.7 million, or $1.23 per share, and $324.4 million in cash, cash equivalents and marketable securities at September 30. The company said its cash is expected to fund planned operations into the second half of 2028. It also reported…